Apyx medical corporation announces fda 510(k) submission with clinical study support for the use of the renuvion® apr handpiece for aesthetic procedures to improve appearance of lax skin

Clearwater, fla.--(business wire)--apyx medical corporation (nasdaq:apyx) (the “company”), a maker of medical devices and supplies and the developer of helium plasma technology, marketed and sold as renuvion® in the cosmetic surgery market and j-plasma® in the hospital surgical market, today announced it has submitted a 510(k) premarket notification (“510(k) submission”) to the u.s. food and drug administration (“fda”). the 510(k) submission is intended to expand its general indication to inclu
APYX Ratings Summary
APYX Quant Ranking